nodes	percent_of_prediction	percent_of_DWPC	metapath
Tasosartan—CYP3A4—Estropipate—osteoporosis	0.137	0.181	CbGbCtD
Tasosartan—CYP3A4—Calcitriol—osteoporosis	0.137	0.181	CbGbCtD
Tasosartan—CYP3A4—Ergocalciferol—osteoporosis	0.11	0.145	CbGbCtD
Tasosartan—CYP3A4—Raloxifene—osteoporosis	0.0917	0.121	CbGbCtD
Tasosartan—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0885	0.117	CbGbCtD
Tasosartan—CYP3A4—Cholecalciferol—osteoporosis	0.0708	0.0934	CbGbCtD
Tasosartan—CYP3A4—Conjugated Estrogens—osteoporosis	0.065	0.0858	CbGbCtD
Tasosartan—CYP3A4—Estradiol—osteoporosis	0.0571	0.0753	CbGbCtD
Tasosartan—AGTR2—ACE Inhibitor Pathway—REN—osteoporosis	0.0389	0.161	CbGpPWpGaD
Tasosartan—AGTR2—ACE Inhibitor Pathway—ACE—osteoporosis	0.0243	0.1	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—REN—osteoporosis	0.0127	0.0524	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—ACE—osteoporosis	0.00791	0.0327	CbGpPWpGaD
Tasosartan—AGTR2—ACE Inhibitor Pathway—TGFB1—osteoporosis	0.00747	0.0309	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.00694	0.0287	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TUBA1B—osteoporosis	0.00549	0.0227	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—PTH1R—osteoporosis	0.00478	0.0198	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CALCR—osteoporosis	0.00478	0.0198	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—CNR2—osteoporosis	0.00404	0.0167	CbGpPWpGaD
Tasosartan—AGTR2—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00375	0.0155	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00322	0.0133	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CALCR—osteoporosis	0.0027	0.0112	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PTH1R—osteoporosis	0.0027	0.0112	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—PTH—osteoporosis	0.00251	0.0104	CbGpPWpGaD
Tasosartan—AGTR1—G alpha (q) signalling events—MGLL—osteoporosis	0.00246	0.0102	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CALCR—osteoporosis	0.00245	0.0101	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PTH1R—osteoporosis	0.00245	0.0101	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CNR2—osteoporosis	0.00245	0.0101	CbGpPWpGaD
Tasosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—osteoporosis	0.00243	0.0101	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—WNT1—osteoporosis	0.0023	0.00952	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MGLL—osteoporosis	0.0022	0.00908	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—ADCY5—osteoporosis	0.00215	0.0089	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—MGLL—osteoporosis	0.00215	0.00888	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—PTHLH—osteoporosis	0.00208	0.00861	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—MGLL—osteoporosis	0.00195	0.00806	CbGpPWpGaD
Tasosartan—AGTR2—Peptide ligand-binding receptors—POMC—osteoporosis	0.00188	0.00776	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—CALCA—osteoporosis	0.00183	0.00758	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SOST—osteoporosis	0.0016	0.00663	CbGpPWpGaD
Tasosartan—AGTR2—G alpha (i) signalling events—POMC—osteoporosis	0.00158	0.00655	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTH1R—osteoporosis	0.00156	0.00644	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CALCR—osteoporosis	0.00156	0.00644	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CALCR—osteoporosis	0.00145	0.006	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTH1R—osteoporosis	0.00145	0.006	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PTH—osteoporosis	0.00142	0.00587	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CNR2—osteoporosis	0.00138	0.00572	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PTH—osteoporosis	0.00129	0.00533	CbGpPWpGaD
Tasosartan—AGTR2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.00126	0.00521	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CNR2—osteoporosis	0.00126	0.0052	CbGpPWpGaD
Tasosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	0.00122	0.00506	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—WNT1—osteoporosis	0.00118	0.00488	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—PTHLH—osteoporosis	0.00118	0.00486	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MGLL—osteoporosis	0.00115	0.00476	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LRP5—osteoporosis	0.00112	0.00465	CbGpPWpGaD
Tasosartan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.00111	0.00459	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LRP6—osteoporosis	0.00108	0.00445	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—PTHLH—osteoporosis	0.00107	0.00442	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.00105	0.00433	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—CALCA—osteoporosis	0.00104	0.00428	CbGpPWpGaD
Tasosartan—AGTR2—GPCR ligand binding—POMC—osteoporosis	0.000959	0.00396	CbGpPWpGaD
Tasosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—osteoporosis	0.000958	0.00396	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—CALCA—osteoporosis	0.000941	0.00389	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—IL1B—osteoporosis	0.000916	0.00379	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TLN1—osteoporosis	0.000908	0.00375	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000881	0.00364	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTH1R—osteoporosis	0.000881	0.00364	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CALCR—osteoporosis	0.000881	0.00364	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00087	0.0036	CbGpPWpGaD
Tasosartan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.00083	0.00343	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTH—osteoporosis	0.000819	0.00338	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTH1R—osteoporosis	0.0008	0.00331	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CALCR—osteoporosis	0.0008	0.00331	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CNR2—osteoporosis	0.000798	0.0033	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—P4HB—osteoporosis	0.000783	0.00324	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTH—osteoporosis	0.000762	0.00315	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—WNT1—osteoporosis	0.00075	0.0031	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—RAP1A—osteoporosis	0.000749	0.00309	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CNR2—osteoporosis	0.000742	0.00307	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—ADCY5—osteoporosis	0.000737	0.00305	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—NFATC1—osteoporosis	0.00073	0.00302	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—DKK1—osteoporosis	0.000725	0.003	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000714	0.00295	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TGFB1—osteoporosis	0.000712	0.00294	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—MGLL—osteoporosis	0.0007	0.00289	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—WNT1—osteoporosis	0.000698	0.00289	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FGA—osteoporosis	0.000679	0.00281	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—PTHLH—osteoporosis	0.000678	0.0028	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—ADCY5—osteoporosis	0.000669	0.00277	CbGpPWpGaD
Tasosartan—AGTR1—Allograft Rejection—TNF—osteoporosis	0.000665	0.00275	CbGpPWpGaD
Tasosartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000637	0.00263	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—MGLL—osteoporosis	0.000635	0.00263	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PTHLH—osteoporosis	0.000631	0.00261	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—BMP2—osteoporosis	0.000631	0.00261	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—FGB—osteoporosis	0.000618	0.00255	CbGpPWpGaD
Tasosartan—AGTR1—Peptide ligand-binding receptors—POMC—osteoporosis	0.000612	0.00253	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—CALCA—osteoporosis	0.000597	0.00247	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PSMA2—osteoporosis	0.000596	0.00247	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—PSMA5—osteoporosis	0.000596	0.00247	CbGpPWpGaD
Tasosartan—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000573	0.00237	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—CALCA—osteoporosis	0.000556	0.0023	CbGpPWpGaD
Tasosartan—AGTR2—GPCR downstream signaling—POMC—osteoporosis	0.000542	0.00224	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000541	0.00224	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SOST—osteoporosis	0.000522	0.00216	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—KL—osteoporosis	0.000505	0.00209	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—POMC—osteoporosis	0.000492	0.00203	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6R—osteoporosis	0.00048	0.00198	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CALCR—osteoporosis	0.000473	0.00195	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTH1R—osteoporosis	0.000473	0.00195	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000463	0.00191	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTH—osteoporosis	0.000463	0.00191	CbGpPWpGaD
Tasosartan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000457	0.00189	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CNR2—osteoporosis	0.000451	0.00186	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTH—osteoporosis	0.00042	0.00174	CbGpPWpGaD
Tasosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.00041	0.0017	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CNR2—osteoporosis	0.000409	0.00169	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—ADCY5—osteoporosis	0.000395	0.00163	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—WNT1—osteoporosis	0.000385	0.00159	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—PTHLH—osteoporosis	0.000383	0.00159	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—SPP1—osteoporosis	0.000382	0.00158	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000379	0.00157	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MGLL—osteoporosis	0.000375	0.00155	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000375	0.00155	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000374	0.00155	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LRP5—osteoporosis	0.000366	0.00151	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LRP6—osteoporosis	0.00035	0.00145	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—PTHLH—osteoporosis	0.000348	0.00144	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS2—osteoporosis	0.000346	0.00143	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—LEP—osteoporosis	0.000338	0.0014	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—CALCA—osteoporosis	0.000338	0.0014	CbGpPWpGaD
Tasosartan—Losartan—ACE—osteoporosis	0.000325	1	CrCbGaD
Tasosartan—AGTR2—Signaling Pathways—ESR1—osteoporosis	0.000323	0.00134	CbGpPWpGaD
Tasosartan—AGTR1—GPCR ligand binding—POMC—osteoporosis	0.000312	0.00129	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—CALCA—osteoporosis	0.000307	0.00127	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IRS1—osteoporosis	0.000302	0.00125	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TLN1—osteoporosis	0.000296	0.00122	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—POMC—osteoporosis	0.000291	0.0012	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6R—osteoporosis	0.000284	0.00117	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IGF1—osteoporosis	0.00028	0.00116	CbGpPWpGaD
Tasosartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000278	0.00115	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—P4HB—osteoporosis	0.000255	0.00105	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTH—osteoporosis	0.000248	0.00103	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—RAP1A—osteoporosis	0.000244	0.00101	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CNR2—osteoporosis	0.000242	0.001	CbGpPWpGaD
Tasosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000241	0.000996	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—ADCY5—osteoporosis	0.00024	0.000993	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—NFATC1—osteoporosis	0.000238	0.000984	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—DKK1—osteoporosis	0.000236	0.000976	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—WNT1—osteoporosis	0.000227	0.00094	CbGpPWpGaD
Tasosartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000226	0.000932	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGA—osteoporosis	0.000221	0.000915	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—ADCY5—osteoporosis	0.000218	0.000901	CbGpPWpGaD
Tasosartan—AGTR2—Signaling by GPCR—IL6—osteoporosis	0.000214	0.000884	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PTHLH—osteoporosis	0.000206	0.00085	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—BMP2—osteoporosis	0.000206	0.00085	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—FGB—osteoporosis	0.000201	0.000832	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	0.000199	0.000824	CbGpPWpGaD
Tasosartan—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	0.000197	0.000813	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PSMA2—osteoporosis	0.000194	0.000803	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—PSMA5—osteoporosis	0.000194	0.000803	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—CALCA—osteoporosis	0.000181	0.000749	CbGpPWpGaD
Tasosartan—AGTR1—GPCR downstream signaling—POMC—osteoporosis	0.000177	0.00073	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—MYC—osteoporosis	0.000168	0.000695	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—TGFB1—osteoporosis	0.000168	0.000693	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—KL—osteoporosis	0.000164	0.00068	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—POMC—osteoporosis	0.00016	0.000663	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6R—osteoporosis	0.000156	0.000647	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ADCY5—osteoporosis	0.000129	0.000532	CbGpPWpGaD
Tasosartan—AGTR2—Signaling Pathways—IL6—osteoporosis	0.000126	0.000522	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—SPP1—osteoporosis	0.000125	0.000515	CbGpPWpGaD
Tasosartan—CYP3A4—Biological oxidations—POMC—osteoporosis	0.00012	0.000495	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PKM—osteoporosis	0.000113	0.000467	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—FDPS—osteoporosis	0.000113	0.000467	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS2—osteoporosis	0.000113	0.000466	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—LEP—osteoporosis	0.00011	0.000456	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PGLS—osteoporosis	0.000107	0.000443	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GPD2—osteoporosis	0.000107	0.000443	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—ESR1—osteoporosis	0.000105	0.000435	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IRS1—osteoporosis	9.84e-05	0.000407	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PNP—osteoporosis	9.8e-05	0.000405	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ATIC—osteoporosis	9.8e-05	0.000405	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—POMC—osteoporosis	9.47e-05	0.000392	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6R—osteoporosis	9.24e-05	0.000382	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IGF1—osteoporosis	9.11e-05	0.000377	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CA2—osteoporosis	8.33e-05	0.000344	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—OXCT1—osteoporosis	8.33e-05	0.000344	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MGLL—osteoporosis	8.12e-05	0.000336	CbGpPWpGaD
Tasosartan—AGTR1—Signaling by GPCR—IL6—osteoporosis	6.97e-05	0.000288	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—IDH2—osteoporosis	6.9e-05	0.000285	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP27A1—osteoporosis	6.49e-05	0.000268	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ACP5—osteoporosis	6.31e-05	0.000261	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—TPI1—osteoporosis	5.87e-05	0.000243	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—P4HB—osteoporosis	5.52e-05	0.000228	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—MYC—osteoporosis	5.48e-05	0.000226	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—TGFB1—osteoporosis	5.46e-05	0.000226	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GAPDH—osteoporosis	5.42e-05	0.000224	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—RAP1A—osteoporosis	5.27e-05	0.000218	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ENO1—osteoporosis	4.26e-05	0.000176	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PSMA2—osteoporosis	4.2e-05	0.000174	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—PSMA5—osteoporosis	4.2e-05	0.000174	CbGpPWpGaD
Tasosartan—AGTR1—Signaling Pathways—IL6—osteoporosis	4.12e-05	0.00017	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—CYP19A1—osteoporosis	3.41e-05	0.000141	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—ADCY5—osteoporosis	2.79e-05	0.000115	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—GPX1—osteoporosis	2.78e-05	0.000115	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—MTHFR—osteoporosis	2.56e-05	0.000106	CbGpPWpGaD
Tasosartan—CYP3A4—Metabolism—POMC—osteoporosis	2.05e-05	8.47e-05	CbGpPWpGaD
